251 related articles for article (PubMed ID: 38347129)
1. The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation.
Li X; Tian S; Shi H; Ta N; Ni X; Bai C; Zhu Z; Chen Y; Shi D; Huang H; Chen L; Hu Z; Qu L; Fang Y; Bai C
Cancer Gene Ther; 2024 May; 31(5):687-697. PubMed ID: 38347129
[TBL] [Abstract][Full Text] [Related]
2. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
PeerJ; 2024; 12():e16923. PubMed ID: 38374950
[TBL] [Abstract][Full Text] [Related]
3. Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature.
Mundada M; Mannan KA; Vasu D; Ahmed F; K S
Turk Patoloji Derg; 2024; 40(2):128-133. PubMed ID: 38265099
[TBL] [Abstract][Full Text] [Related]
4. All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC.
Rekhtman N
Clin Cancer Res; 2024 May; 30(9):1708-1711. PubMed ID: 38416596
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract][Full Text] [Related]
6. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract][Full Text] [Related]
7. An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement.
Hanona PF; Ezekwudo D; Fullmer J; Allen T; Jaiyesimi I
Thorac Cancer; 2024 Apr; 15(10):847-851. PubMed ID: 38390699
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.
Chen J; Zheng Q; Wang J; Zhang X; Lv Y
Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
[TBL] [Abstract][Full Text] [Related]
9. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
10. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors].
Cao XN; Li Z; Wang QY
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
[No Abstract] [Full Text] [Related]
12. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract][Full Text] [Related]
13. Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure.
Shi L; Lin L; Ding Y; Zeng Y; Chen X
Front Oncol; 2022; 12():1020875. PubMed ID: 36452500
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
[TBL] [Abstract][Full Text] [Related]
15. Thoracic SMARCA4-deficient undifferentiated tumor.
Jiang J; Chen Z; Gong J; Han N; Lu H
Discov Oncol; 2023 Apr; 14(1):51. PubMed ID: 37115343
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy].
Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma.
Li X; Shi H; Zhang W; Bai C; He M; Ta N; Huang H; Ning Y; Fang C; Qin H; Dong Y
Front Oncol; 2021; 11():690115. PubMed ID: 34660264
[TBL] [Abstract][Full Text] [Related]
18. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract][Full Text] [Related]
19. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
[TBL] [Abstract][Full Text] [Related]
20. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
